Glucagon-like peptide-1 agonists are used in the treatment of type 2 diabetes and obesity. Long-acting GLP-1 RAs approved for use in the U.S include: dulaglutide (Trulicity), exenatide extended-release (Bydureon), liraglutide (Victoza), and semaglutide (Ozempic).
The global GLP-1 receptor agonist market is estimated to be valued at US$ 12,720.6 million in 2021 and is expected to exhibit a CAGR of 6.1% over the forecast period (2022-2028).
Click To get Free SAMPLE PDF (Including Full TOC, List of Tables & Figures, Chart) @
Approval and launch of new products is expected to propel growth of the global GLP-1 receptor agonist market over the forecast period. For instance, the U.S. Food and Drug Administration approved two additional doses of Eli Lilly and Company’s GLP-1 receptor agonist drug, Trulicity (dulaglutide) used for the treatment of type-2 diabetes, in September 2020.
Moreover, high prevalence of diabetes is also expected to propel growth of the global GLP-1 receptor agonist market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.
R&D of new products is expected to offer lucrative growth opportunities for players in the global GLP-1 receptor agonist market. For instance, 9 Meters Biopharma, Inc., in July 2020, started a clinical trial to assess the efficacy and safety of its drug candidate NM-002, a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of short bowel syndrome.
Covid-19 Impact Analysis:
Higher BMI increases the risk of COVID-19 infection. According to a study published by the World Obesity Federation, around 10.5% of positive COVID-19 test results in the U.S were due to obesity during March 1, 2020 and May 14, 2020. Such scenario is expected to boost demand for GLP-1 receptor agonist.
Ask for PDF Brochure @
Asia Pacific is expected to witness significant growth in the global GLP-1 receptor agonist market, owing to high prevalence of obesity in the region. For instance, the combined prevalence of obesity in Australia is expected to increase from 26% in 2019 to 35% by 2025, according to a study published in Nature in May 2021.
Major players operating in the global GLP-1 receptor agonist market are focused on approval and launch of new products to expand their product portfolio. For example, the European Medicines Agency, in April 2020, approved Rybelsus (semaglutide) from Novo Nordisk A/S for the treatment of Type-2 diabetes.
Side effects of certain drugs have led to decline in their sale, which is expected to limit growth of the global GLP-1 receptor agonist market over the forecast period. For example, GlaxoSmithKline plc, in July 2017, withdrew Tanzeum (albiglutide) from the market as sales of the GLP-1 receptor agonist drug declined majorly due to risk of renal impairment, pancreatitis, and diabetic ketoacidosis in diabetic patients.
Major players operating in the global GLP-1 receptor agonist market include, Amylin Pharmaceuticals, Inc., Amgen Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc, Hanmi Pharm. Co., Ltd., Intarcia Therapeutics, Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Novo Nordisk A/S, PegBio Co., Ltd., Pfizer Inc., Sanofi, Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
Reasons to Buy this GLP-1 Receptor Agonist Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging GLP-1 Receptor Agonist market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging GLP-1 Receptor Agonist market
➡Leading company profiles reveal details of key GLP-1 Receptor Agonist market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging GLP-1 Receptor Agonist market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 GLP-1 Receptor Agonist Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: GLP-1 Receptor Agonist Industry Impact
Chapter 2 Global GLP-1 Receptor Agonist Competition by Types, Applications, and Top Regions and Countries
2.1 Global GLP-1 Receptor Agonist (Volume and Value) by Type
2.3 Global GLP-1 Receptor Agonist (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global GLP-1 Receptor Agonist Sales, Consumption, Export, Import by Regions
Chapter 5 North America GLP-1 Receptor Agonist Market Analysis
Chapter 6 East Asia GLP-1 Receptor Agonist Market Analysis
Chapter 7 Europe GLP-1 Receptor Agonist Market Analysis
Chapter 8 South Asia GLP-1 Receptor Agonist Market Analysis
Chapter 9 Southeast Asia GLP-1 Receptor Agonist Market Analysis
Chapter 10 Middle East GLP-1 Receptor Agonist Market Analysis
Chapter 11 Africa GLP-1 Receptor Agonist Market Analysis
Chapter 12 Oceania GLP-1 Receptor Agonist Market Analysis
Chapter 13 South America GLP-1 Receptor Agonist Market Analysis
Chapter 14 Company Profiles and Key Figures in GLP-1 Receptor Agonist Business
Chapter 15 Global GLP-1 Receptor Agonist Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027